An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

伊布替尼 弥漫性大B细胞淋巴瘤 淋巴瘤 间质细胞 套细胞淋巴瘤 生物 转录组 免疫疗法 癌症研究 慢性淋巴细胞白血病 肿瘤微环境 免疫系统 免疫学 白血病 遗传学 基因表达 基因
作者
Chloé B. Steen,Bogdan Luca,Mohammad Shahrokh Esfahani,Barzin Y. Nabet,Brian J. Sworder,Farshad Farshidfar,Kiarash Shamardani,David M. Kurtz,Chih Long Liu,Ranjana H. Advani,Yasodha Natkunam,June H. Myklebust,Maximilian Diehn,Andrew J. Gentles,Aaron M. Newman,Ash A. Alizadeh
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 655-655 被引量:4
标识
DOI:10.1182/blood-2019-129461
摘要

Background: Diffuse large B cell lymphoma (DLBCL) exhibits significant clinical and biological heterogeneity, in part due to cell-of-origin subtypes, somatic alterations, and diverse stromal constituents within the tumor microenvironment (TME). Several immunologically-active lymphoma therapies are known to rely on innate and adaptive anti-tumor responses occurring within this dynamic TME, including agents that are approved (e.g., rituximab, lenalidomide, CART19, ibrutinib) or emerging (e.g., anti-CD47, checkpoint inhibitors). We hypothesized that a large-scale characterization of the cellular heterogeneity in DLBCL might reveal previously unknown biological variation in the TME linked to tumor subtypes and genotypes, therapeutic responses and clinical outcomes, with implications for future personalization of immunotherapy. Methods: Using a combination of lymphoma single-cell RNA sequencing (scRNA-seq) and bulk tumor transcriptome deconvolution (CIBERSORTx; Newman et al., Nat Biotech, 2019), we developed a new machine learning framework for identifying cellular states and ecosystems that reflect fundamental TME subtypes and distinctions in tumor biology (Fig. 1). Specifically, using CIBERSORTx, we purified the transcriptomes of B cells and 12 different TME cell types, including immune and stromal subsets, from 1,279 DLBCL tumor biopsies profiled in 3 prior studies (Reddy et al., Cell 2017; Schmitz et al., NEJM 2018; Chapuy et al., Nat Med 2018). Then, we defined distinct transcriptional states for each of the 13 cell types, which we validated at single-cell resolution, using a combination of two scRNA-seq techniques (Smart-Seq2 and 10x Chromium 5' GEP, BCR and TCR) to profile primary DLBCL, FL, and human tonsils, as well as leveraging multiple scRNA-seq datasets from previous studies. We identified robust co-associations between cell states that form tumor cellular ecosystems, which we validated in independent datasets of bulk DLBCL tumor gene expression profiles. Finally, we related TME ecosystems to defined tumor subtypes, including genotype classes, and to clinical outcomes. Results: By systematically characterizing the landscape of cellular heterogeneity in nearly 1,300 DLBCL tumors, we defined an atlas of 49 distinct transcriptional states across 13 major cell types. These novel cell states spanned diverse innate and adaptive immune effector cells of the lymphoid and myeloid lineages, as well as tumor-associated fibroblasts. Remarkably, 94% of these states (46 of 49) could be validated in a compendium of ~200,000 single-cell transcriptomes derived from lymphomas, healthy control tonsils, and other tissue types. Moreover, single cells from DLBCL, FL and tonsils best mirrored these newly discovered cell states. We next characterized the biology and potential clinical utility of each cell state. We observed clear distinctions in the transcriptional programs of immune and stromal elements between germinal center and activated B cell DLBCL, as well as between known mutational subtypes. Importantly, many cell states reflected novel phenotypic groupings, and the majority were significantly associated with overall survival (P<0.05). These findings were highly concordant both within and across 3 independent DLBCL cohorts. By identifying groups of DLBCL patients with similar communities of cellular states, we defined cohesive cellular ecosystems that collectively capture the landscape of transcriptional heterogeneity in DLBCL tumors. Patients whose tumors were assigned to these ecosystems exhibited striking variation in overall survival. Importantly, the ecosystems defined distinct subgroups that could not be fully recapitulated by known transcriptional and genetic subtypes. Moreover, several TME classes showed significant enrichments in canonical or novel tumor genotypes, suggesting an evolutionary interplay between the tumor and host microenvironment. Conclusion: We describe a novel computational framework to digitally dissect the DLBCL TME and an atlas of novel states for diverse cell types in these tumors. We show how cellular states form cohesive tumor ecosystems, which exhibit distinct clinical outcomes and novel somatic alterations. These results expand our understanding of cellular heterogeneity in DLBCL, with implications for the development of individualized immunotherapies. Disclosures Kurtz: Roche: Consultancy. Advani:Kura: Research Funding; Merck: Research Funding; Millennium: Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Regeneron: Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cell Medica, Ltd: Consultancy; Kyowa Kirin Pharmaceutical Developments, Inc.: Consultancy; Stanford University: Employment, Equity Ownership; Janssen: Research Funding; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Research Funding; Infinity Pharma: Research Funding; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Celmed: Consultancy, Membership on an entity's Board of Directors or advisory committees; Forty-Seven: Research Funding; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead Sciences, Inc./Kite Pharma, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Autolus: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agensys: Research Funding. Diehn:Roche: Consultancy; AstraZeneca: Consultancy; Novartis: Consultancy; BioNTech: Consultancy; Quanticell: Consultancy. Alizadeh:Janssen: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; Chugai: Consultancy; Celgene: Consultancy; Gilead: Consultancy; Roche: Consultancy; Pfizer: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
何靖发布了新的文献求助10
刚刚
1秒前
yy完成签到,获得积分10
1秒前
1秒前
KKK完成签到,获得积分10
2秒前
情怀的应助被zcyuqing采纳,获得10
2秒前
彭于晏的应助被zcyuqing采纳,获得10
2秒前
zero发布了新的文献求助10
2秒前
慕青的应助被zcyuqing采纳,获得10
2秒前
李爱国的应助被zcyuqing采纳,获得10
2秒前
CodeCraft的应助被zcyuqing采纳,获得10
2秒前
cfw完成签到,获得积分10
2秒前
2秒前
小蘑菇的应助被zcyuqing采纳,获得10
2秒前
可爱的函函的应助被zcyuqing采纳,获得10
2秒前
传奇3的应助被zcyuqing采纳,获得10
2秒前
科研通AI6.2的应助被zcyuqing采纳,获得10
2秒前
卡巴涛的应助被zcyuqing采纳,获得10
3秒前
redfcg完成签到,获得积分10
3秒前
zl12345完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
花三万俩发布了新的文献求助10
4秒前
5秒前
Akim的应助被so采纳,获得10
5秒前
KKK发布了新的文献求助10
5秒前
karma完成签到,获得积分20
5秒前
完美世界的应助被敏感寻真采纳,获得10
5秒前
小二郎的应助被Huimin采纳,获得10
5秒前
可靠的书桃完成签到,获得积分10
5秒前
Lucas的应助被COCO采纳,获得10
5秒前
小小完成签到,获得积分10
6秒前
cfw发布了新的文献求助10
6秒前
彭于晏的应助被炭烤草莓采纳,获得10
6秒前
张少伟发布了新的文献求助10
6秒前
温柔樱桃发布了新的文献求助10
7秒前
今后的应助被明前易拉罐采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170166
求助须知:如何正确求助?哪些是违规求助? 9563213
关于积分的说明 21768986
捐赠科研通 7761665
什么是DOI,文献DOI怎么找? 3430630
关于科研通互助平台的介绍 2554458
邀请新用户注册赠送积分活动 2475393